Page 25 - ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
China Focus: Claim that Chinese researchers hid coronavirus data defies scientific ethics - China News
sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.
COVID-19 survivors may possess wide-ranging resistance to the disease
emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
COVID-19 survivors may possess wide-ranging resistance to the disease
emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
Reuters Reuters
21 July, 2021, 2:10 pm
Vials labelled Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic
CHICAGO, July 20 (Reuters) – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks – known as correlates of protection – to evaluate flu vaccines without requiring large, lengthy clinical trials.
Jul 21, 2021
CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks known as correlates of protection to evaluate flu vaccines without requiring large, lengthy clinical trials.
“You could use it to predict efficacy from a vaccine, which will be more important as we are less able to conduct placebo-controlled trials,” said Stanley Plotkin, inventor of the Rubella vaccine and an expert on correlates of protection.